Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
On February 17, 2026, Baird initiated coverage of Caris Life Sciences, Inc. (NASDAQ:CAI) with an Outperform rating and a $26 price target. Baird described Caris Life Sciences, Inc.








